10.12.18
Almac Diagnostic Services has announced a significant investment in a new Illumina NovaSeq 6000 sequencer which will benefit Biopharma clients’ biomarker discovery and clinical trial projects.
The addition of the NovaSeq’s powerful processing capabilities to Almac’s existing range of NGS platform offerings will allow for larger sample runs, greater read depth, and faster speeds. The new instrument will also ultimately reduce sample turnaround times and increase variant detection quality and accuracy for clients.
With the NovaSeq, Almac will be able to sequence the transcriptomes of up to ~384 samples, per run (dual flow cell, 50M reads per sample) in a timeframe as short as 36 hours. The NovaSeq provides scalable throughput and flexibility for virtually any sequencing method, genome, and scale of project. To accommodate NovaSeq’s high capacity and efficiency, Almac has also invested in appropriate informatics infrastructure and installed high speed uplinks to cloud based providers.
The NovaSeq will form an integral part of Almac’s current DNA and RNA Sequencing offerings and future offerings for Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES).
Michael Sloan, global vice president of Commercial Operations, Almac Diagnostic Services said, “We are excited about the potential benefits the NovaSeq will be able to bring to our customers with its sequencing capabilities enhancing our current DNA and RNA NGS panel offerings to the market. We are positioning ourselves at the cutting edge of NGS diagnostics and the investment in this new NGS platform will help Almac to continue to play a leading role within stratified medicine.”